TITLE

Addressing your patients' concerns on BCG vaccine

AUTHOR(S)
Baxter, David
PUB. DATE
October 2002
SOURCE
Pulse;10/21/2002, Vol. 62 Issue 40, p59
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Reports on the withdrawal of Bacille Calmette Guerin (BCG) tuberculosis (TB) vaccine in Great Britain. Background on the BCG vaccine; Reasons for the withdrawal of the TB vaccine from the market; Role of TB vaccines in the control of tuberculosis in England and Wales; Tips for general practice physicians on how to address their patients' concerns regarding BCG vaccine.
ACCESSION #
7700569

 

Related Articles

  • `Poor' vaccine ruled out in TB puzzle. Day, Michael // New Scientist;7/13/96, Vol. 151 Issue 2038, p14 

    Reports on a British study designed to explain why the BCG vaccine often fails to protect against tuberculosis (TB) in developing countries. Rejection of notion that poor quality of vaccines render the TB treatment ineffective; Exposure of children in tropical countries to numerous other...

  • Improving vaccines against tuberculosis. Britton, Warwick J; Palendira, Umaimainthan // Immunology & Cell Biology;Feb2003, Vol. 81 Issue 1, p34 

    Summary Tuberculosis remains a major cause of mortality and physical and economic deprivation worldwide. There have been significant recent advances in our understanding of the Mycobacterium tuberculosis genome, mycobacterial genetics and the host determinants of protective immunity....

  • TB vaccine failure was predictable. Beverley, Peter // Nature;11/28/2013, Vol. 503 Issue 7477, p469 

    A letter to the editor is presented related to the role of the MVA85A vaccine, a tuberculosis (TB) vaccine, in the protection of TB over the Bacillus Calmette–Guérin (BCG) vaccine.

  • Editorial Response: Variation in Clinical and Immune Responses to Bacille Calmette-Guerin--Implications for an Improved Tuberculosis Vaccine.  // Clinical Infectious Diseases;4/1/1999, Vol. 28 Issue 4, p791 

    Comments on an article about the variation in clinical and immune responses to the tuberculosis vaccine bacille Calmette-Gu é rin. Concerns on the effectiveness of the vaccine; Observations on the duration of vaccine-induced ulceration; Need for further study to determine the limitations of...

  • BCG in Britain.  // British Medical Journal;9/27/1980, Vol. 281 Issue 6244, p825 

    Assesses the efficacy of BCG vaccination in treating tuberculosis in Great Britain. Mode of transmission of tuberculosis; Reduction in the incidence of tuberculosis; Complications of BCG vaccination.

  • BCG campaign may be delayed.  // Pulse;8/19/2002, Vol. 62 Issue 32, p8 

    Reports on the possible delay of the start of the BCG school vaccination campaign in Great Britain due in October 2002, following the withdrawal of the only tuberculosis vaccine approved in the country.

  • New TB vaccination programme.  // Practice Nurse;7/29/2005, Vol. 30 Issue 2, p7 

    This article reports that the British government will replace the universal BCG vaccination program with a program of targeted vaccination for individuals that have the greatest risk.

  • BCG vaccine works well in preventing TB. Rodman, Morton J.; Hurley, Mary Lou // RN;May94, Vol. 57 Issue 5, p82 

    Reports on a study on the efficacy of Bacillus Calmette-Guerin (BCG) vaccine in preventing tuberculosis infection. Consideration of broader use of the vaccine in the country; Analysis of prospective trials and case-control studies.

  • TB vaccines move a step closer. Berger, Abi // New Scientist;5/27/95, Vol. 146 Issue 1979, p19 

    Reports on University of Surrey researchers' perfection of a gene replacement technique which could speed up the search for new tuberculosis vaccines to replace BCG. Removal of the part of a bacterium that spreads the infection as core process of vaccine development; Identification of virulent...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics